CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

sevoflurane

Trade name: ultane

Small moleculeapproved

Approved

Jun 7, 1995

Sevoflurane is a general anesthetic that is FDA approved for the induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor. Common adverse reactions include cardiovascular: bradyarrhythmia, hypotension, gastrointestinal: nausea, vomiting, neurologic: somnolence, psychiatric: agitation, respiratory: cough, interrupted breathing and other: shivering. — NCATS

Clinical trial activity

531 trials · 396 clinical orgs · 7 marketing orgs

Phase 1
27
Phase 2
73
Phase 3
43
Phase 4
185

Earliest trial started Aug 1, 1996 (NCT00000259)

Timeline

1990s

  1. Jun 7, 1995

    AbbVie — Earliest FDA Approval

  2. Jun 7, 1995

    AbbVie — NDA Secondary Org

  3. Jun 7, 1995

    AbbVie — NDA Organization

  4. Jan 1, 1997

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jul 2, 2002

    Baxalta — Marketing Organization

  2. Jul 2, 2002

    Baxter — Marketing Organization

  3. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  4. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

  5. May 2, 2007

    Piramal — Marketing Organization

  6. Nov 19, 2007

    Halocarbon Products — Marketing Organization

2010s

  1. Nov 3, 2015

    Hengrui Therapeutics, Inc. — Marketing Organization

2020s

  1. Aug 18, 2023

    Shandong Lanjin Pharmaceuticals Co.,Ltd — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJun 7, 1995

Chemistry & pharmacology

Loading structure…

SMILES

FCOC(C(F)(F)F)C(F)(F)F
Mol. weight
200.0548 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane
  • 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane
  • bax 3084
  • fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
  • fluoromethyl hexafluoroisopropyl ether
  • mr6s4
  • mr6s4
  • mr-6s4
  • mr-6s4
  • sevoflo
  • sevofluorane
  • sevofluran
  • sevofluran
  • sevofluran
  • sevoflurane
  • sevoflurane
  • sevoflurane
  • sevoflurane
  • sevoflurane
  • sevoflurane
  • sevoflurane
  • sevoflurane
  • sevoflurane
  • sevoflurane
  • sevoflurane
  • sevoflurano
  • sevoflurano
  • sevofluranum
  • sevofluranum
  • sevofrane
  • sevorane
  • sevorane
  • sevorane
  • sevorane
  • sojourn
  • sojourn
  • ultane
  • ultane
  • ultane
  • ultane

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07295158N/AJan 1, 2026Konya City Hospital
NCT07271459N/ADec 31, 2025Ain Shams University
NCT07304206N/ADec 8, 2025Inonu University
NCT07268872N/ANov 21, 2025Henan Provincal People's Hospital
NCT07192549N/ASep 15, 2025Ningxia Medical University
NCT07181564N/ASep 11, 2025University of Patras
NCT07152912N/ASep 4, 2025Ain Shams University
NCT07123870Phase 4Jul 23, 2025Kocaeli City Hospital
NCT06907823N/AJun 30, 2025Pusan National University
NCT07035782N/AJun 30, 2025Wenzhou Medical University
NCT07016308N/AJun 10, 2025Harran University
NCT06788743N/AJun 1, 2025Xijing Hospital
NCT07304479N/AMay 1, 2025University of Athens
NCT06832683N/AMar 31, 2025Kocaeli City Hospital
NCT06779890Phase 4Mar 1, 2025Aristotle University of Thessaloniki
NCT06773351Phase 4Feb 1, 2025Huazhong University of Science and Technology, Sichuan University
NCT07062367N/AFeb 1, 2025Tanta University
NCT06729086N/AJan 4, 2025Saint-Joseph University
NCT06560268Phase 4Nov 4, 2024Cukurova University
NCT06457958Phase 4Nov 1, 2024Kocaeli City Hospital, The Scientific and Technological Research Council of Turkey
Showing 20 of 531 trials
Page 1 / 27

Organizations

Research & Development (396)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Yonsei UniversityAcademic/Hospital161622010
Seoul National UniversityAcademic/Hospital131322010
University of ZurichAcademic/Hospital111142004
University Clermont AuvergneAcademic/Hospital101042008
Konkuk UniversityAcademic/Hospital9932007
Mansoura UniversityAcademic/Hospital9712015
Nanjing Medical UniversityAcademic/Hospital9922007
Capital Medical UniversityAcademic/Hospital8542014
Inonu UniversityAcademic/Hospital8822011
Tanta UniversityAcademic/Hospital8822019
University of TorontoAcademic/Hospital8732006
Harvard UniversityAcademic/Hospital7652013
Huazhong University of Science and TechnologyAcademic/Hospital7622009
Kangbuk Samsung HospitalAcademic/Hospital7722015
People's Liberation Army of ChinaGovernment7522011
University of RochesterAcademic/Hospital7522006
BaxaltaFor profit6122008
Fudan UniversityAcademic/Hospital6632015
University of ParisAcademic/Hospital6242009
Ain Shams UniversityAcademic/Hospital5522021
396 organizations
Page 1 / 20

Marketing (8)

OrganizationOrg typeRelationshipDate
AbbVieFor profitNDA2Jun 7, 1995
AbbVieFor profitNDAJun 7, 1995
BaxaltaFor profitMKTGJul 2, 2002
BaxterFor profitMKTGJul 2, 2002
Halocarbon ProductsFor profitMKTGNov 19, 2007
Hengrui Therapeutics, Inc.For profitMKTGNov 3, 2015
PiramalFor profitMKTGMay 2, 2007
Shandong Lanjin Pharmaceuticals Co.,LtdFor profitMKTGAug 18, 2023